tiprankstipranks
Advertisement
Advertisement

DE:7V3 Stock Latest News

Cantargia Showcases Promising Nadunolimab Data in Hard-to-Treat Colorectal Cancer
Company AnnouncementsCantargia Showcases Promising Nadunolimab Data in Hard-to-Treat Colorectal Cancer
6d ago
Cantargia to Court Investors at Van Lanschot Kempen Life Sciences Conference
PremiumCompany Announcements
Cantargia to Court Investors at Van Lanschot Kempen Life Sciences Conference
19d ago
Cantargia to Highlight Antibody Platform at TD Cowen Healthcare Conference
PremiumCompany Announcements
Cantargia to Highlight Antibody Platform at TD Cowen Healthcare Conference
29d ago
Cantargia: Solid Cash Runway and Expanding Nadunolimab Pipeline Support Buy Rating and Long-Term Upside
PremiumRatings
Cantargia: Solid Cash Runway and Expanding Nadunolimab Pipeline Support Buy Rating and Long-Term Upside
1M ago
Cantargia Highlights Pipeline Progress in 2025 Year-End Report
PremiumCompany Announcements
Cantargia Highlights Pipeline Progress in 2025 Year-End Report
1M ago
Cantargia Sets Date for 2025 Annual Results and Investor Presentation
PremiumCompany AnnouncementsCantargia Sets Date for 2025 Annual Results and Investor Presentation
2M ago
Cantargia to Engage Investors at Leerink Global Healthcare Conference
Premium
Company Announcements
Cantargia to Engage Investors at Leerink Global Healthcare Conference
2M ago
Expanding Nadunolimab’s Oncology Footprint: Low-Cost MSS-CRC Study De-Risks Pivotal Pancreatic Program and Supports Buy Rating on Cantargia AB
Premium
Ratings
Expanding Nadunolimab’s Oncology Footprint: Low-Cost MSS-CRC Study De-Risks Pivotal Pancreatic Program and Supports Buy Rating on Cantargia AB
2M ago
Cantargia Begins US Trial of Nadunolimab Combo in Hard-to-Treat Colorectal Cancer
PremiumCompany Announcements
Cantargia Begins US Trial of Nadunolimab Combo in Hard-to-Treat Colorectal Cancer
2M ago
Cantargia AB: Strategic Focus on PDAC and Autoimmune Indications Amid TRIFOUR Study Setback
PremiumRatings
Cantargia AB: Strategic Focus on PDAC and Autoimmune Indications Amid TRIFOUR Study Setback
4M ago
Cantargia Reports TRIFOUR Study Results on Nadunolimab
PremiumCompany Announcements
Cantargia Reports TRIFOUR Study Results on Nadunolimab
4M ago
Cantargia AB: Strategic Partnerships and Financial Stability Drive Buy Rating
PremiumRatings
Cantargia AB: Strategic Partnerships and Financial Stability Drive Buy Rating
4M ago
Cantargia AB Releases Interim Report Highlighting Strategic Progress
PremiumCompany AnnouncementsCantargia AB Releases Interim Report Highlighting Strategic Progress
4M ago
Cantargia AB Announces Nomination Committee for 2026 AGM
Premium
Company Announcements
Cantargia AB Announces Nomination Committee for 2026 AGM
4M ago
Cantargia AB to Release Interim Report and Host Investor Presentation
Premium
Company Announcements
Cantargia AB to Release Interim Report and Host Investor Presentation
5M ago
Cantargia AB: Promising Oncology Pipeline and Strategic Partnership Drive Buy Rating
PremiumRatings
Cantargia AB: Promising Oncology Pipeline and Strategic Partnership Drive Buy Rating
5M ago
Cantargia AB to Present at Key Investor Conferences
PremiumCompany Announcements
Cantargia AB to Present at Key Investor Conferences
5M ago
Cantargia AB Appoints New Chief Medical Officer to Enhance Oncology Focus
PremiumCompany Announcements
Cantargia AB Appoints New Chief Medical Officer to Enhance Oncology Focus
6M ago
Cantargia Completes CAN10 Program Sale to Otsuka for Up to $613 Million
PremiumCompany Announcements
Cantargia Completes CAN10 Program Sale to Otsuka for Up to $613 Million
6M ago
Cantargia Secures US Patent for Nadunolimab, Boosting Market Position
PremiumCompany AnnouncementsCantargia Secures US Patent for Nadunolimab, Boosting Market Position
7M ago
Cantargia AB’s Mid-Year Report Highlights Progress in Antibody-Based Drug Development
Premium
Company Announcements
Cantargia AB’s Mid-Year Report Highlights Progress in Antibody-Based Drug Development
7M ago
Cantargia AB Appoints Dr. Hilde Steineger as New CEO
Premium
Company Announcements
Cantargia AB Appoints Dr. Hilde Steineger as New CEO
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >